Multiple Sclerosis study: Acute Intermittent Hypoxia
Official title Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS
ClinicalTrials.gov ID: NCT06390930
What this study is testing
- What it's testing
- The study wants to find out if short periods of low oxygen breathing change brain and spinal cord signals and improve arm and hand function in people with MS.
- Who it's for
- Adults with multiple sclerosis, including relapsing‑remitting or secondary progressive types.
- What's involved
- Participants will breathe short low‑oxygen bursts while researchers measure muscle responses and brain signals to the arm muscles before and after the breathing sessions.
- Time commitment
- The study lasts a few weeks, with several visits for breathing sessions and tests of arm and hand function.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Diagnosis of relapsing-remitting MS according to the McDonald criteria, over 5 years ago
- Relapse free for at least 6 months
- Expanded Disability Status Scale (EDSS) ≤7
- Index finger abduction strength \ 20 seconds in at least one hand
- Stable disease modifying therapies for at least 6 months
You likely can't join if
- Another diagnosis (e.g., peripheral neuropathies or orthopedic) affecting upper limb function
- Mini-Mental State Examination (MMSE) score \<24
- Modified Ashworth Scale score \>3 on elbow joint
- Uncontrolled hypertension or hypotension (outside 140/90 and 85/55 mmHg)
- History of epilepsy, chronic obstructive pulmonary disease, or sleep apnea
- Unstable medical conditions, ongoing upper limb therapy, or musculoskeletal pain
See the full eligibility criteria
- Diagnosis of relapsing-remitting MS according to the McDonald criteria, over 5 years ago
- Relapse free for at least 6 months
- Expanded Disability Status Scale (EDSS) ≤7
- Index finger abduction strength \ 20 seconds in at least one hand
- Stable disease modifying therapies for at least 6 months
- Individuals taking dalfampridine will be eligible if taking the same daily dose for at least 2 months prior to screening
- Another diagnosis (e.g., peripheral neuropathies or orthopedic) affecting upper limb function
- Mini-Mental State Examination (MMSE) score \<24
- Modified Ashworth Scale score \>3 on elbow joint
- Uncontrolled hypertension or hypotension (outside 140/90 and 85/55 mmHg)
- History of epilepsy, chronic obstructive pulmonary disease, or sleep apnea
- Unstable medical conditions, ongoing upper limb therapy, or musculoskeletal pain
- Pregnancy as confirmed by urine test
The study team makes the final eligibility decision.
Where it is enrolling
- Chicago, Illinois, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Chicago, Illinois, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.